The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors.
Open accessAbstract
The rapid clearance of circulating liposomes from the bloodstream, coupled with their high uptake by liver and spleen, has thus far been an obstacle to any attempts at targeting to tumors. We have assessed the impact of liposome composition on their clearance from the circulation in normal and tumor-bearing mice and on their uptake by tumors and various normal tissues. By selective changes in lipid composition, while maintaining a mean particle diameter of approximately equal to 100 nm, we have achieved up to a 60-fold increase in the fraction of recovered dose present in blood 24 hr after i.v. injection. Concomitantly, there was a decrease by a factor of 4 of the recovered dose localizing in the liver and spleen, the major organs of the reticuloendothelial system. Parallel experiments in tumor-bearing mice demonstrated a 25-fold increase of the liposome concentration in the tumor when formulations with long and short blood residence time were compared. The most favorable results were obtained with liposomes containing a small molar fraction of a negatively charged glycolipid, such as monosialoganglioside or phosphatidylinositol, and a solid-phase neutral phospholipid as the bulk component. The bio-distribution of such formulations is of considerable therapeutic potential in cancer for increasing the concentration of cytotoxic agents in tumors while minimizing the likelihood of toxicity to the reticuloendothelial system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphorus Assay in Column Chromatography
Bartlett, G. R. (1959) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)70226-3 · Cited by 12,801
Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes
Olson, F., Hunt, C. A., Szoka, F. C., Vail, W. J., & Papahadjopoulos, D. (1979) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(79)90085-3 · Cited by 1,126
Self-citationPapahadjopoulos, D., Jacobson, K., Nir, S., & Isac, I. (1973) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(73)90314-3 · Cited by 997
Self-citationLarge unilamellar liposomes with low uptake into the reticuloendothelial system
Allen, T. M., & Chonn, A. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)80506-9 · Cited by 729
An electron microscopic study of the fenestrated endothelial lining of rat liver sinusoids
Wisse, E. (1970) · Journal of Ultrastructure Research · doi:10.1016/s0022-5320(70)90150-4 · Cited by 652
Fate and behavior of liposomes in vivo: a review of controlling factors.
Senior, J. H. (1987) · PubMed · Cited by 591
Diffusion and convection in normal and neoplastic tissues.
Swabb, E. A., Wei, J., & Gullino, P. M. (1974) · PubMed · Cited by 399
Senior, J., & Gregoriadis, G. (1982) · Life Sciences · doi:10.1016/0024-3205(82)90455-6 · Cited by 355
Poste, G. H., Bucana, C. D., Raz, A., Bugelski, P. J., Kirsh, R. L., & Fidler, I. J. (1982) · PubMed · Cited by 309
Lopez-Berestein, G., Mehta, R., Hopfer, R. L., Mills, K., Kasi, L., Mehta, K., Fainstein, V., Luna, M., Hersh, E. M., & Juliano, R. (1983) · Journal of Infectious Diseases · doi:10.1093/infdis/147.5.939 · Cited by 303
Cited by
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
“These PK, BD, and imaging data suggest that the reduced clinical toxicity of OLV-DOX results from a somewhat lower peak level of free drug and possibly some changes in the tissue distribution of the liposomes, with a partial shift toward drug accumulation in the RES at the expense of other tissues.”
BackgroundMethodInfluentialLong-Circulating and Target-Specific Nanoparticles: Theory to Practice
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01494-7 · Cited by 3,515
Bertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824
Liposomes as nanomedical devices
Bozzuto, G., & Molinari, A. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s68861 · Cited by 2,261
Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes
Klibanov, A. L., Maruyama, K., Torchilin, V. P., & Huang, L. (1990) · FEBS Letters · doi:10.1016/0014-5793(90)81016-h · Cited by 2,027
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
Feng, S.-S. (2006) · Nanomedicine · doi:10.2217/17435889.1.3.297 · Cited by 1,951
Langer, R. (1990) · Science · doi:10.1126/science.2218494 · Cited by 1,778
Pharmacokinetics of Pegylated Liposomal Doxorubicin: Review of Animal and Human Studies
Gabizon, A., Shmeeda, H., & Barenholz, Y. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342050-00002 · Cited by 1,634
Self-citationPapahadjopoulos, D., Allen, T. M., Gabizon, A., Mayhew, E., Matthay, K., Huang, S. K., Lee, K. D., Woodle, M. C., Lasic, D. D., & Redemann, C. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.24.11460 · Cited by 1,620
Self-citationNew developments in liposomal drug delivery
Pattni, B. S., Chupin, V. V., & Torchilin, V. P. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00046 · Cited by 1,600
Drug Delivery with Carbon Nanotubes for In vivo Cancer Treatment
Liu, Z., Chen, K., Davis, C., Sherlock, S., Cao, Q., Chen, X., & Dai, H. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1468 · Cited by 1,348
Optimizing Liposomes for Delivery of Chemotherapeutic Agents to Solid Tumors
Drummond, D. C., Meyer, O., Hong, K., Kirpotin, D. B., & Papahadjopoulos, D. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01426-1 · Cited by 1,263
Self-citationLiposomes in drug delivery: Progress and limitations
Sharma, A. (1997) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(97)00135-x · Cited by 1,253
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
Hare, J. I., Lammers, T., Ashford, M. B., Puri, S., Storm, G., & Barry, S. T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.025 · Cited by 1,214
Multidrug resistance (MDR) in cancer
Krishna, R., & Mayer, L. D. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00114-7 · Cited by 1,026
Nichols, J. W., & Bae, Y. H. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.057 · Cited by 834
Application of liposomes in medicine and drug delivery
Daraee, H., Etemadi, A., Kouhi, M., Alimirzalu, S., & Akbarzadeh, A. (2016) · Artificial Cells, Nanomedicine, and Biotechnology · doi:10.3109/21691401.2014.953633 · Cited by 765
Targeted pharmaceutical nanocarriers for cancer therapy and imaging
Torchilin, V. P. (2007) · The AAPS Journal · doi:10.1208/aapsj0902015 · Cited by 762
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come
Yingchoncharoen, P., Kalinowski, D. S., & Richardson, D. R. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012070 · Cited by 744
Biodistribution and delivery efficiency of unmodified tumor-derived exosomes
Smyth, T., Kullberg, M., Malik, N., Smith-Jones, P., Graner, M. W., & Anchordoquy, T. J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.013 · Cited by 722
The journey of a drug-carrier in the body: An anatomo-physiological perspective
Bertrand, N., & Leroux, J.-C. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.098 · Cited by 707
Long circulating microparticulate drug carriers
Stolnik, S., Illum, L., & Davis, S. S. (1995) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(95)00025-3 · Cited by 700
Folate Receptor-Mediated Drug Targeting: From Therapeutics to Diagnostics
Hilgenbrink, A. R., & Low, P. S. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20457 · Cited by 625
Multifunctional and stimuli-sensitive pharmaceutical nanocarriers
Torchilin, V. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.09.026 · Cited by 583
“Various long-circulating nanocarriers have been shown to effectively accumulate in many tumors via the EPR effect [7-9, 43].”
BackgroundAndresen, T. L., Jensen, S. S., & Jørgensen, K. (2005) · Progress in Lipid Research · doi:10.1016/j.plipres.2004.12.001 · Cited by 580
Passive and Active Drug Targeting: Drug Delivery to Tumors as an Example
Torchilin, V. P. (2010) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-00477-3_1 · Cited by 573
Shaping Cancer Nanomedicine: The Effect of Particle Shape on The In Vivo Journey of Nanoparticles
Toy, R., Peiris, P. M., Ghaghada, K. B., & Karathanasis, E. (2014) · Nanomedicine · doi:10.2217/nnm.13.191 · Cited by 570
Delivery of Therapeutic Proteins
Pisal, D. S., Kosloski, M. P., & Balu-Iyer, S. V. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22054 · Cited by 532
The 60-year evolution of lipid nanoparticles for nucleic acid delivery
Cullis, P. R., & Felgner, P. L. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00977-6 · Cited by 503
Schroeder, A., Kost, J., & Barenholz, Y. (2009) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2009.08.003 · Cited by 485
On the formulation of pH-sensitive liposomes with long circulation times
Simões, S. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.10.038 · Cited by 483
Extracellular vesicles as drug delivery systems: Lessons from the liposome field
van der Meel, R., Fens, M. H. A. M., Vader, P., van Solinge, W. W., Eniola-Adefeso, O., & Schiffelers, R. M. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.07.049 · Cited by 482
Current status of pH-sensitive liposomes in drug delivery
Drummond, D. C., Zignani, M., & Leroux, J.-C. (2000) · Progress in Lipid Research · doi:10.1016/s0163-7827(00)00011-4 · Cited by 477
Gabizon, A. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.01.011 · Cited by 464
Self-citationBiodistribution, Clearance, and Long‐Term Fate of Clinically Relevant Nanomaterials
Bourquin, J., Milosevic, A., Hauser, D., Lehner, R., Blank, F., Petri‐Fink, A., & Rothen‐Rutishauser, B. (2018) · Advanced Materials · doi:10.1002/adma.201704307 · Cited by 461
Chonn, A., Semple, S. C., & Cullis, P. R. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)37026-7 · Cited by 460
Ligand-targeted liposomal anticancer drugs
Sapra, P., & Allen, T. M. (2003) · Progress in Lipid Research · doi:10.1016/s0163-7827(03)00032-8 · Cited by 438
Nagayasu, A., Uchiyama, K., & Kiwada, H. (1999) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(99)00041-1 · Cited by 437
van der Koog, L., Gandek, T. B., & Nagelkerke, A. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202100639 · Cited by 418
Liposomal Delivery Systems: Design Optimization and Current Applications
Abu Lila, A. S., & Ishida, T. (2017) · Biological & Pharmaceutical Bulletin · doi:10.1248/bpb.b16-00624 · Cited by 382
Challenges in Development of Targeted Liposomal Therapeutics
Sawant, R. R., & Torchilin, V. P. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9330-0 · Cited by 379
Li, Y., Kröger, M., & Liu, W. K. (2015) · Nanoscale · doi:10.1039/c5nr02970h · Cited by 376
PEG–PLGA copolymers: Their structure and structure-influenced drug delivery applications
Zhang, K., Tang, X., Zhang, J., Lu, W., Lin, X., Zhang, Y., Tian, B., Yang, H., & He, H. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.026 · Cited by 374
Silica-based mesoporous nanoparticles for controlled drug delivery
Kwon, S., Singh, R. K., Perez, R. A., Abou Neel, E. A., Kim, H.-W., & Chrzanowski, W. (2013) · Journal of Tissue Engineering · doi:10.1177/2041731413503357 · Cited by 370
Mori, A., Klibanov, A. L., Torchilin, V. P., & Huang, L. (1991) · FEBS Letters · doi:10.1016/0014-5793(91)80699-4 · Cited by 369
Developments in liposomal drug delivery systems
Maurer, N., Fenske, D. B., & Cullis, P. R. (2001) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.1.6.923 · Cited by 344
Dos Santos, N., Allen, C., Doppen, A.-M., Anantha, M., Cox, K. A. K., Gallagher, R. C., Karlsson, G., Edwards, K., Kenner, G., Samuels, L., et al. (2007) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2006.12.013 · Cited by 341
Stealth Properties to Improve Therapeutic Efficacy of Drug Nanocarriers
Salmaso, S., & Caliceti, P. (2013) · Journal of Drug Delivery · doi:10.1155/2013/374252 · Cited by 340
Torchilin, V. P. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.031 · Cited by 332
Surface Engineering of Liposomes for Stealth Behavior
Nag, O., & Awasthi, V. (2013) · Pharmaceutics · doi:10.3390/pharmaceutics5040542 · Cited by 322
Allen, T. M. (1994) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(94)90016-7 · Cited by 321
Ultrasound triggered release of cisplatin from liposomes in murine tumors
Schroeder, A., Honen, R., Turjeman, K., Gabizon, A., Kost, J., & Barenholz, Y. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.03.007 · Cited by 305
Self-citationNanotechnology applied to overcome tumor drug resistance
Gao, Z., Zhang, L., & Sun, Y. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.05.051 · Cited by 303
Charrois, G. J. R., & Allen, T. M. (2004) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2004.03.006 · Cited by 300
Stabilized plasmid-lipid particles: construction and characterization
Wheeler, J. J., Palmer, L., Ossanlou, M., MacLachlan, I., Graham, R. W., Zhang, Y. P., Hope, M. J., Scherrer, P., & Cullis, P. R. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300821 · Cited by 299
Recent Developments of Liposomes as Nanocarriers for Theranostic Applications
Xing, H., Hwang, K., & Lu, Y. (2016) · Theranostics · doi:10.7150/thno.15464 · Cited by 296
Targeted liposomal drug delivery: a nanoscience and biophysical perspective
Liu, Y., Castro Bravo, K. M., & Liu, J. (2021) · Nanoscale Horizons · doi:10.1039/d0nh00605j · Cited by 294
pH-Sensitive liposomes-principle and application in cancer therapy
Karanth, H., & Murthy, R. S. R. (2007) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.59.4.0001 · Cited by 294
Preparation of micelle-forming polymer-drug conjugates
Yokoyama, M., Kwon, G. S., Okano, T., Sakurai, Y., Seto, T., & Kataoka, K. (1992) · Bioconjugate Chemistry · doi:10.1021/bc00016a007 · Cited by 294
Petersen, G. H., Alzghari, S. K., Chee, W., Sankari, S. S., & La-Beck, N. M. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.04.028 · Cited by 290
Evolution and clinical translation of drug delivery nanomaterials
Hassan, S., Prakash, G., Bal Ozturk, A., Saghazadeh, S., Farhan Sohail, M., Seo, J., Remzi Dokmeci, M., Zhang, Y. S., & Khademhosseini, A. (2017) · Nano Today · doi:10.1016/j.nantod.2017.06.008 · Cited by 288
Forssen, E., & Willis, M. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00083-5 · Cited by 287
Perspectives on the past, present, and future of cancer nanomedicine
Youn, Y. S., & Bae, Y. H. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.05.008 · Cited by 285
Biswas, S., Dodwadkar, N. S., Deshpande, P. P., & Torchilin, V. P. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.009 · Cited by 279
Stealth nanoparticles in oncology: Facing the PEG dilemma
Zalba, S., ten Hagen, T. L. M., Burgui, C., & Garrido, M. J. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.09.002 · Cited by 278
Torchilin, V. P., Levchenko, T. S., Lukyanov, A. N., Khaw, B. A., Klibanov, A. L., Rammohan, R., Samokhin, G. P., & Whiteman, K. R. (2001) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2728(01)00165-7 · Cited by 271
The protein corona and its effects on nanoparticle-based drug delivery systems
Li, H., Wang, Y., Tang, Q., Yin, D., Tang, C., He, E., Zou, L., & Peng, Q. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.05.019 · Cited by 265
Mechanisms and kinetics of liposome–cell interactions
Düzgüneş, N., & Nir, S. (1999) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(99)00037-x · Cited by 261
Wang, H., Chen, Q., & Zhou, S. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00399d · Cited by 260
Novel Temperature-Sensitive Liposomes with Prolonged Circulation Time
Lindner, L. H., Eichhorn, M. E., Eibl, H., Teichert, N., Schmitt-Sody, M., Issels, R. D., & Dellian, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0035 · Cited by 258
Liposome circulation time and tumor targeting: implications for cancer chemotherapy
Gabizon, A. A. (1995) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(95)00030-b · Cited by 255
Self-citationpH-sensitive biomaterials for drug delivery
Zhuo, S., Zhang, F., Yu, J., Zhang, X., Yang, G., & Liu, X. (2020) · Molecules · doi:10.3390/molecules25235649 · Cited by 247
Xu, L., & Anchordoquy, T. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22243 · Cited by 209
Polymeric micelles of biodegradable diblock copolymers: enhanced encapsulation of hydrophobic drugs
Hussein, Y. H. A., & Youssry, M. (2018) · Materials · doi:10.3390/ma11050688 · Cited by 196
“Due to steric repulsion [119], the outer PEG shell of the micelle inhibits the surface adsorption of proteins and other biological components in the bloodstream so that there is no recognition by the RES (such as the liver, kidney, or spleen) [114], achieving higher circulation half-time in the body [101,120,121] and…”
BackgroundCurrent advances in non‐viral gene delivery systems: Liposomes versus extracellular vesicles
Belhadj, Z., Qie, Y., Carney, R. P., Li, Y., & Nie, G. (2023) · BMEMat · doi:10.1002/bmm2.12018 · Cited by 79
Yao, Q., Dai, Z., Hoon Choi, J., Kim, D., & Zhu, L. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b09511 · Cited by 71
Dual targeted extracellular vesicles regulate oncogenic genes in advanced pancreatic cancer
Chiang, C.-L., Ma, Y., Hou, Y.-C., Pan, J., Chen, S.-Y., Chien, M.-H., Zhang, Z.-X., Hsu, W.-H., Wang, X., Zhang, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42402-3 · Cited by 63
Ligand-functionalized nanoliposomes for targeted delivery of galantamine
Mufamadi, M. S., Choonara, Y. E., Kumar, P., Modi, G., Naidoo, D., van Vuuren, S., Ndesendo, V. M. K., Toit, L. C. D., Iyuke, S. E., & Pillay, V. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.03.037 · Cited by 51
High-resolution 3D visualization of nanomedicine distribution in tumors
Moss, J. I., Barjat, H., Emmas, S.-A., Strittmatter, N., Maynard, J., Goodwin, R. J. A., Storm, G., Lammers, T., Puri, S., Ashford, M. B., et al. (2020) · Theranostics · doi:10.7150/thno.37178 · Cited by 19
“This time point was selected for distribution analysis as it corresponds to peak liposome accumulation in tumors [33-37].”
Metadata
- Authors
- Gabizon, A., & Papahadjopoulos, D.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1988-09
- Volume
- 85
- Issue
- 18
- Pages
- 6949-6953
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2009038500
- Cited by
- 1,131
- References
- 36
- FWCI
- 16.27
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.